Advertisement

Neurological Sciences

, Volume 39, Issue 8, pp 1423–1430 | Cite as

Different clinical response to interferon beta and glatiramer acetate related to the presence of oligoclonal IgM bands in CSF in multiple sclerosis patients

  • Bonaventura Casanova
  • Laura Lacruz
  • María Luisa Villar
  • José Andrés Domínguez
  • María Carcelén Gadea
  • Francisco Gascón
  • Javier Mallada
  • David Hervás
  • María Simó-Castelló
  • José Carlos Álvarez-Cermeño
  • Carmen Calles
  • Javier Olascoaga
  • Lluís Ramió-Torrentà
  • Carmen Alcalá
  • Angeles Cervelló
  • Isabel Boscá
  • Francisco Carlos Pérez-Mirallles
  • Francisco Coret
Original Article

Abstract

Objective

To study the efficacy of interferon beta (IFNβ) and glatiramer acetate (GA) related to the presence of oligoclonal M bands (OCMB) in the cerebrospinal fluid in relapsing-remitting multiple sclerosis (RRMS).

Method

This is an observational, multicenter and retrospective study with prospectively collected data of patients that started treatment with IFNβ or GA. Treatment decision was made blinded to the OCMB status. Time to first attack after starting therapy was compared by using Kaplan-Meier curves, and adjustment by Cox regression analysis was performed.

Results

Two hundred and fifty-six patients entered in the study (141–55% received IFNβ; 115–45% received GA). After a mean follow-up of 41 and 65 months, 54.7% of patients remained free from further attacks (RF). The proportion of RF patients was higher in the GA group than in the IFNβ group (72.2 vs. 40.4%, p < 0.001). The IFNβ patients with OCMB+ presented the poorest response, 31.3% RF vs. 48.1% in IFNβ without OCMB, p = 0.03.

Conclusion

OCMB in CSF could be a biomarker of treatment response in multiple sclerosis.

Keywords

Relapsing-remitting multiple sclerosis Beta interferon Glatiramer acetate Oligoclonal M bands 

References

  1. 1.
    The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43(4):655–661CrossRefGoogle Scholar
  2. 2.
    Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Wolinsky JS, Copolymer 1 Multiple Sclerosis Study Group (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45(7):1268–1276CrossRefPubMedGoogle Scholar
  3. 3.
    Jacobs LD, Cookfair DL, Rudick RA et al (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39(3):285–294CrossRefPubMedGoogle Scholar
  4. 4.
    Ebers GC, Hommes O, Hughes RAC, Kappos L et al (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneous in Multiple Sclerosis) Study Group. Lancet 352(9139):1498–1504CrossRefGoogle Scholar
  5. 5.
    Khan O, Rieckmann P, Boyko A, Selmaj K, Zivadinov R (2013) GALA Study Group. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol 73(6):705–713CrossRefPubMedGoogle Scholar
  6. 6.
    Kieseier BC, Arnold DL, Balcer LJ et al (2015) Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE. Mult Scler 21(8):1025–1035CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    O'Connor P, Filippi M, Arnason B et al (2009) 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 8(10):889–897CrossRefPubMedGoogle Scholar
  8. 8.
    Mikol DD, Barkhof F, Chang P et al (2008 Oct) Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 7(10):903–914CrossRefPubMedGoogle Scholar
  9. 9.
    Lublin FD, Cofield SS, Cutter GR et al (2013) Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol 73(3):327–340CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Thangarajh M, Gomez-Rial J, Hedström AK et al (2008) Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis. Mult Scler 14(9):1208–1213CrossRefPubMedGoogle Scholar
  11. 11.
    Villar L, García-Barragán N, Espiño M et al (2008) Influence of oligoclonal IgM specificity in multiple sclerosis disease course. Mult Scler 14(2):183–187CrossRefPubMedGoogle Scholar
  12. 12.
    Magraner MJ, Bosca I, Simó-Castelló M, García-Martí G, Alberich-Bayarri A, Coret F, Álvarez-Cermeño JC, Martí-Bonmatí L, Villar LM, Casanova B (2012) Brain atrophy and lesion load are related to CSF lipid-specific IgM oligoclonal bands in clinically isolated syndromes. Neuroradiology 54(1):5–12CrossRefPubMedGoogle Scholar
  13. 13.
    Mandrioli J, Sola P, Bedin R, Gambini M, Merelli E (2008) A multifactorial prognostic index in multiple sclerosis. Cerebrospinal fluid IgM oligoclonal bands and clinical features to predict the evolution of the disease. J Neurol 255(7):1023–1031CrossRefPubMedGoogle Scholar
  14. 14.
    Ferraro D, Simone AM, Bedin R et al (2013) Cerebrospinal fluid oligoclonal IgM bands predict early conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome. J Neuroimmunol 257(1–2):76–81CrossRefPubMedGoogle Scholar
  15. 15.
    Villar LM, Casanova B, Ouamara N et al (2014) Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis. Ann Neurol 76(2):231–240CrossRefPubMedGoogle Scholar
  16. 16.
    Bosca I, Villar LM, Coret F et al (2010) Response to interferon in multiple sclerosis is related to lipid-specific oligoclonal IgM bands. Mult Scler 16(7):810–815CrossRefPubMedGoogle Scholar
  17. 17.
    Espiño M, Abraira V, Arroyo R, Bau L, Cámara C, Campos-Ruiz L, Casanova B, Espejo C, Fernández O, García-Merino A, García-Sánchez MI, Gómez M, Gosis A, Izquierdo G, Meca J, Montalban X, Morandeira F, Olascoaga J, Prada A, Quintana E, Ramió-Torrentà L, Rodríguez-Antigüedad A, Salgado G, Santiago JL, Sarasola E, Simó-Castelló M, Alvarez-Cermeño JC, Villar LM (2015) Assessment of the reproducibility of oligoclonal IgM band detection for its application in daily clinical practice. Clin Chim Acta 438:67–69CrossRefPubMedGoogle Scholar
  18. 18.
    Polman CH, Reingold SC, Edan G et al (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald criteria”. Ann Neurol 28:840–856CrossRefGoogle Scholar
  19. 19.
    Kurtzke J (1983) Rating neurological impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 33:1444–1452CrossRefPubMedGoogle Scholar
  20. 20.
    Roxburgh RH, Seaman SR, Masterman T, et al. Multiple sclerosis severity score: using disability and disease duration to rate disease severity. Neurology;64(7):1144–51Google Scholar
  21. 21.
    Schubert RD, Hu Y, Kumar G et al (2015) IFN-β treatment requires B cells for efficacy in neuroautoimmunity. J Immunol 194(5):2110–2116CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Annuziata P, Giorgio A, De Santi L et al (2006) Absence of cerebrospinal fluid oligoclonal bands is associated with desalyed disability progression in relapsing-remitting MS patients treated with interferon-β. L Neurol Sci 244:97–102CrossRefGoogle Scholar
  23. 23.
    Kappos L, Freedman MS, Polman CH et al (2009) Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 8(11):987–997CrossRefPubMedGoogle Scholar
  24. 24.
    Polman CH, Reingold SC, Banwell B et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Dobson R, Ramagopalan S, Davis A, Giovannoni G (2013) Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude. J Neurol Neurosurg Psychiatry 84(8):909–914CrossRefPubMedGoogle Scholar
  26. 26.
    Tintoré M, Rovira À, Río J et al (2015) Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain 138:1863–1874CrossRefPubMedGoogle Scholar
  27. 27.
    Haas J, Firzlaff M (2005) Twenty-four-month comparison of immunomodulatory treatments—a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone). Eur J Neurol 12(6):425–431CrossRefPubMedGoogle Scholar
  28. 28.
    Castelli-Haley J, Oleen-Burkey MA, Lage MJ, Johnson KP (2009) Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis. Adv Ther 26(5):552–562CrossRefPubMedGoogle Scholar
  29. 29.
    La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, Gandini A, Longobardi A, Weinstock-Guttman B, Vaona A (2014) Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 7:CD009333Google Scholar

Copyright information

© Springer-Verlag Italia S.r.l., part of Springer Nature 2018

Authors and Affiliations

  • Bonaventura Casanova
    • 1
  • Laura Lacruz
    • 1
  • María Luisa Villar
    • 2
  • José Andrés Domínguez
    • 3
  • María Carcelén Gadea
    • 4
  • Francisco Gascón
    • 3
  • Javier Mallada
    • 5
  • David Hervás
    • 6
  • María Simó-Castelló
    • 1
  • José Carlos Álvarez-Cermeño
    • 7
  • Carmen Calles
    • 8
  • Javier Olascoaga
    • 9
  • Lluís Ramió-Torrentà
    • 10
  • Carmen Alcalá
    • 1
  • Angeles Cervelló
    • 4
  • Isabel Boscá
    • 1
  • Francisco Carlos Pérez-Mirallles
    • 1
  • Francisco Coret
    • 3
  1. 1.Neuroimmunology UnitHospital Universitari i Politècnic La FeValenciaSpain
  2. 2.Immunology ServiceHospital Ramón y Cajal de MadridMadridSpain
  3. 3.Neuroimmunology UnitHospital Clínic Universitari de ValènciaValenciaSpain
  4. 4.Neurological ServiceHospital General de ValènciaValenciaSpain
  5. 5.Neurological ServiceHospital de EldaAlicanteSpain
  6. 6.Biostatistical UnitInstitut d’Investigació Sanitaria La FeValenciaSpain
  7. 7.Neurological ServiceHospital Ramón y Cajal de MadridMadridSpain
  8. 8.Neurological ServiceHospital Son EspasesMallorcaSpain
  9. 9.Neurological ServiceHospital de DonostiSan SebastianSpain
  10. 10.Neuroimmunology and Multiple Sclerosis Unit, Hospital Dr. Josep TruetaIDIBGIGironaSpain

Personalised recommendations